# Kartos Therapeutics > Kartos Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company in Redwood City, California, developing navtemadlin (KRT-232), an oral MDM2 inhibitor that restores p53 activity in tumours with wild-type TP53. Founded in 2016 by Wayne Rothbaum around an MDM2 asset in-licensed from Amgen, the company's lead programme is in myelofibrosis. Kartos runs no developer program and publishes no product API; the only machine-readable surface reachable without credentials is the WordPress REST content API behind kartosthera.com. This file was GENERATED by API Evangelist on 2026-08-04 from the company's public website and the live route index at https://kartosthera.com/wp-json/. Kartos Therapeutics does not publish an llms.txt of its own (/llms.txt returns 404), and publishes no robots.txt either. ## Company - [Kartos Therapeutics](https://kartosthera.com/): Company homepage. - [About](https://kartosthera.com/about/): Founding, leadership, board and investors. - [Science](https://kartosthera.com/science/): The MDM2/p53 mechanism and how navtemadlin works. - [Research](https://kartosthera.com/research/): The clinical programme and expanded access. - [Presentations & Publications](https://kartosthera.com/presentations/): Congress abstracts and posters. - [Advocacy](https://kartosthera.com/advocacy/): Patient advocacy resources. - [Contact](https://kartosthera.com/contact/): 275 Shoreline Drive, Suite 300, Redwood City, CA 94065; info@kartosthera.com; +1 650.542.0130. - [Privacy Policy](https://kartosthera.com/privacy-policy/): Privacy policy and terms of use. ## Clinical programme - POIESIS — Phase 3, myelofibrosis, navtemadlin added to ruxolitinib, recruiting (NCT06479135). - KRT-232-109 — Phase 1b/2, myelofibrosis with suboptimal ruxolitinib response, active not recruiting (NCT04485260). - BOREAS — Phase 3, JAK-inhibitor relapsed/refractory myelofibrosis, navtemadlin versus best available therapy, active not recruiting (NCT03662126). - Reported clinical activity also in acute myeloid leukaemia and Merkel cell carcinoma. Navtemadlin targets tumours with wild-type TP53. ## APIs - [Kartos Therapeutics Content API](https://kartosthera.com/wp-json): The WordPress REST API behind kartosthera.com. Anonymously readable, no key required. 183 registered routes; 21 operations verified readable without credentials. - [WordPress REST API Handbook](https://developer.wordpress.org/rest-api/): The upstream contract that defines the wp/v2 namespace. Kartos publishes no documentation of its own for this surface. ## Specs - [OpenAPI (derived)](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/openapi/kartos-therapeutics-content-openapi.yml): OpenAPI 3.1.0 derived by API Evangelist from the live route index; only anonymously readable operations are modelled. - [Overlay](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/overlays/kartos-therapeutics-content-overlay.yaml): The API Evangelist enhancements applied on top of the provider's route index. - [apis.yml](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/apis.yml): The APIs.json 0.20 index for this provider. ## The two collections worth reading - `GET https://kartosthera.com/wp-json/wp/v2/presentation` — 5 navtemadlin congress abstracts and posters, including the POIESIS Phase 3 study design and the BOREAS Phase 3 results. Each links to a PDF in the media library. - `GET https://kartosthera.com/wp-json/wp/v2/team` — 15 executive, board and advisor records with structured `acf.team-job-title`, `acf.team-credentials` and `acf.team-bio` fields. ## Artifacts - [Authentication](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/authentication/kartos-therapeutics-authentication.yml): No credential needed to read; application passwords are advertised but not obtainable by third parties. - [Conventions](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/conventions/kartos-therapeutics-conventions.yml): Pagination, sparse fieldsets, context scoping, error envelope, CORS and security headers. - [Error catalog](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/errors/kartos-therapeutics-problem-types.yml): 13 observed WordPress REST error codes. Not RFC 9457. - [Data model](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/data-model/kartos-therapeutics-data-model.yml): Entity graph across pages, presentations, team members and media. - [Conformance](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/conformance/kartos-therapeutics-conformance.yml): What this surface does and does not conform to. - [Lifecycle](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/lifecycle/kartos-therapeutics-lifecycle.yml): No versioning policy, no deprecation policy, no SLA, no status page. - [Well-known](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/well-known/kartos-therapeutics-well-known.yml): Every /.well-known/ path returns 404. - [Domain security](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/security/kartos-therapeutics-domain-security.yml): TLS 1.3 and HSTS present; no DNSSEC, no CAA, no DMARC. - [Agent skills](https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/skills/_index.yml): Packaged operating instructions for reading this surface. ## Optional - [Secondary-market listing](https://forgeglobal.com/kartos-therapeutics_stock/): Forge Global page for Kartos Therapeutics private stock. - [LinkedIn](https://www.linkedin.com/company/kartos-therapeutics) ## Notes for agents - Everything catalogued here is a safe, anonymous, read-only GET. No key, no token, no sign-up. - There is no rate-limit signalling on this surface. Be conservative: cache results and keep request volume low. - The `posts` collection is empty and the `/news/`, `/careers/` and `/pipeline/` paths do not exist. Do not infer a press-release archive. - No agent card, no MCP server and no webhook or event surface exists for this provider. Do not assume one. - API responses carry `X-Robots-Tag: noindex`, and the site serves no robots.txt. Treat the surface as incidental rather than offered, and do not build a dependency on it.